1.0" ?> 20250HR__008599INT 99 INTRODUCED 2026-02-12 REVISED 2026-02-19 2025 0 HR 85 INT Introduced by Assembly Member Nguyen (Coauthors: Assembly Members Aguiar-Curry, Ahrens, Alanis, Arambula, Ávila Farías, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Calderon, Caloza, Castillo, Chen, Connolly, Davies, DeMaio, Fong, Gabriel, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lackey, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Rivas, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Stefani, Ta, Tangipa, Valencia, Wallis, Ward, Wicks, Wilson, and Zbur) LEAD_AUTHOR ASSEMBLY Nguyen COAUTHOR ASSEMBLY Aguiar-Curry COAUTHOR ASSEMBLY Ahrens COAUTHOR ASSEMBLY Alanis COAUTHOR ASSEMBLY Arambula COAUTHOR ASSEMBLY Ávila Farías COAUTHOR ASSEMBLY Bauer-Kahan COAUTHOR ASSEMBLY Bennett COAUTHOR ASSEMBLY Berman COAUTHOR ASSEMBLY Boerner COAUTHOR ASSEMBLY Bonta COAUTHOR ASSEMBLY Calderon COAUTHOR ASSEMBLY Caloza COAUTHOR ASSEMBLY Castillo COAUTHOR ASSEMBLY Chen COAUTHOR ASSEMBLY Connolly COAUTHOR ASSEMBLY Davies COAUTHOR ASSEMBLY DeMaio COAUTHOR ASSEMBLY Fong COAUTHOR ASSEMBLY Gabriel COAUTHOR ASSEMBLY Garcia COAUTHOR ASSEMBLY Gipson COAUTHOR ASSEMBLY Jeff Gonzalez COAUTHOR ASSEMBLY Mark González COAUTHOR ASSEMBLY Hadwick COAUTHOR ASSEMBLY Haney COAUTHOR ASSEMBLY Harabedian COAUTHOR ASSEMBLY Hart COAUTHOR ASSEMBLY Hoover COAUTHOR ASSEMBLY Irwin COAUTHOR ASSEMBLY Jackson COAUTHOR ASSEMBLY Johnson COAUTHOR ASSEMBLY Kalra COAUTHOR ASSEMBLY Krell COAUTHOR ASSEMBLY Lackey COAUTHOR ASSEMBLY Lee COAUTHOR ASSEMBLY Lowenthal COAUTHOR ASSEMBLY Macedo COAUTHOR ASSEMBLY McKinnor COAUTHOR ASSEMBLY Muratsuchi COAUTHOR ASSEMBLY Ortega COAUTHOR ASSEMBLY Pacheco COAUTHOR ASSEMBLY Papan COAUTHOR ASSEMBLY Patel COAUTHOR ASSEMBLY Patterson COAUTHOR ASSEMBLY Pellerin COAUTHOR ASSEMBLY Petrie-Norris COAUTHOR ASSEMBLY Quirk-Silva COAUTHOR ASSEMBLY Ramos COAUTHOR ASSEMBLY Ransom COAUTHOR ASSEMBLY Rivas COAUTHOR ASSEMBLY Michelle Rodriguez COAUTHOR ASSEMBLY Rogers COAUTHOR ASSEMBLY Blanca Rubio COAUTHOR ASSEMBLY Sanchez COAUTHOR ASSEMBLY Schiavo COAUTHOR ASSEMBLY Schultz COAUTHOR ASSEMBLY Sharp-Collins COAUTHOR ASSEMBLY Solache COAUTHOR ASSEMBLY Stefani COAUTHOR ASSEMBLY Ta COAUTHOR ASSEMBLY Tangipa COAUTHOR ASSEMBLY Valencia COAUTHOR ASSEMBLY Wallis COAUTHOR ASSEMBLY Ward COAUTHOR ASSEMBLY Wicks COAUTHOR ASSEMBLY Wilson COAUTHOR ASSEMBLY Zbur Relative to Angelman Syndrome Awareness Day. Angelman Syndrome Awareness Day

WHEREAS, Angelman syndrome is a rare neurogenetic disorder that occurs in 1 in 15,000 live births and affects approximately 500,000 individuals worldwide; and

WHEREAS, Angelman syndrome is caused by a loss of function of the UBE3A gene in chromosome 15 derived from the mother, and a gene that is needed to develop and control speech and movement; and

WHEREAS, Individuals with Angelman syndrome begin experiencing developmental delays starting from 6 and 12 months of age, inclusive, and these developmental delays are often the first signs of Angelman syndrome; and

WHEREAS, In addition to delayed development, Angelman syndrome causes problems with speech and balance, mental disability, and sometimes seizures; and

WHEREAS, Angelman syndrome shares symptoms and characteristics with other disorders, including autism, cerebral palsy, and Prader-Willi syndrome; and

WHEREAS, Individuals with Angelman syndrome have an overall happy and excitable demeanor, and they smile and laugh often; and

WHEREAS, Angelman syndrome is rare. Most individuals with Angelman syndrome do not have a family history of the syndrome, and researchers often do not know what causes the genetic changes that result in the disease; and

WHEREAS, Angelman syndrome can lead to several complications, including trouble feeding, hyperactivity, sleep troubles, scoliosis, and obesity; and

WHEREAS, The treatment of Angelman syndrome focuses on managing medical, sleep, and developmental issues; and

WHEREAS, There is currently no cure for Angelman syndrome, but organizations such as the Angelman Syndrome Foundation note that with further research, there may be a cure in the future; and

WHEREAS, Organizations worldwide recognize February 15 as International Angelman Day to raise awareness about Angelman syndrome; now, therefore, be it

Resolved by the Assembly of the State of California, That the Assembly hereby recognizes February 15, 2026, as Angelman Syndrome Awareness Day; and be it further

Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution. REVISIONS: Heading—Line 2.